首页> 中文期刊> 《上海医药》 >2009-2011年上海医院心血管系统疾病用药分析

2009-2011年上海医院心血管系统疾病用药分析

         

摘要

Objective:To investigate the trend of cardiovascular disease medication in Shanghai sample hospitals in recent years. Methods:We statistically analyzed the data of drugs sales, sorting, and growth rate and so on and discussed their clinical application in cardiovascular disease in 119 sample hospitals from 2009 to 2011 in Shanghai. Results:The drug sales used in cardiovascular disease is as the second largest category after the anti-infective drugs with a compound annual growth rate of 11.81%. The leading drug sales included tablets of Ginkgo biloba L extract, amlodipine, valsartan, fermented cordyceps preparations. The growth rate for tablets of Ginkgo biloba L extract, salvianolate telmisartan, irbesartan and erigeron elements is more rapid than the others. Conclusions:Drugs used in cardiovascular disease are a large class of commonly used ones with gradually increasing demand and their market is prospective.%  目的:了解近年来上海医院心血管系统疾病用药的情况和变化趋势.方法:统计2009-2011年上海119家样本医院心血管系统疾病用药销售金额、排序和增长率等,结合临床应用进行分析和讨论.结果:心血管系统疾病用药金额仅次于抗感染类药物,列为第2大类,复合年均增长率11.81%.用药金额领先品种有银杏叶制剂、氨氯地平、缬沙坦、发酵虫草制剂等,增速较快的有银杏叶制剂、丹参多酚酸盐、替米沙坦、厄贝沙坦和灯盏花素等.结论:心血管系统用药是一大类常用药物,需求量逐渐增大,市场前景广阔.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号